| 3.38 0.07 (2.11%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.04 | 1-year : | 4.72 |
| Resists | First : | 3.46 | Second : | 4.04 |
| Pivot price | 3.27  |
|||
| Supports | First : | 3.27 | Second : | 3.15 |
| MAs | MA(5) : | 3.37 |
MA(20) : | 3.26 |
| MA(100) : | 3.05 |
MA(250) : | 2.79 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.4  |
D(3) : | 70.4 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 3.6 | Low : | 2.27 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRON ] has closed below upper band by 16.8%. Bollinger Bands are 2.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.41 | 3.41 - 3.43 |
| Low: | 3.27 - 3.28 | 3.28 - 3.3 |
| Close: | 3.35 - 3.38 | 3.38 - 3.41 |
Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dance brands, reaching consumers through online sales, traditional retail outlets, and partnerships within the hospitality sector. Beyond hemp, the company also engages in the cultivation, production, and commercialization of cannabis and its related extracts for both therapeutic and recreational consumption. Its cannabis offerings encompass dried flower, pre-rolled joints, edibles, concentrates, and various extracts, which are distributed via wholesale channels and directly to clients. The wellness segment operates under the PEACE NATURALS platform, while its adult-use products are marketed through the Spinach brand. Additionally, Cronos exports dried cannabis and cannabis oils to international markets such as Germany, Israel, and Australia. Founded in 2012, the company's headquarters are located in Toronto, Canada.
Tue, 27 Oct 2026
Does the CanAdelaar Deal Change the Story at Cronos Group (NASDAQ:CRON)? - Kalkine Media
Tue, 27 Oct 2026
Cronos Group (TSX:CRON): Should This Penny Stock Be On Watchlists? - Kalkine Media
Mon, 26 Oct 2026
Can Cronos Group (NASDAQ:CRON) Benefit From Major Cannabis Reform? - Kalkine Media
Mon, 26 Oct 2026
Cronos Group Inc. (CRON) latest stock news and headlines - Yahoo Finance Singapore
Fri, 23 Oct 2026
Cronos Group (NASDAQ:CRON) shares in focus as cannabis stocks themes shift today - Kalkine Media
Thu, 22 Oct 2026
Healthcare Watch: What Could Put Cronos Group Inc. (TSX:CRON) on Investors’ Radar Next - kalkine.ca
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 368 (M) |
| Shares Float | 187 (M) |
| Held by Insiders | 49.1 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 3,370 (K) |
| Shares Short P.Month | 3,240 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.88 |
| Profit Margin | 39 % |
| Operating Margin | 15.4 % |
| Return on Assets (ttm) | -0.2 % |
| Return on Equity (ttm) | 7 % |
| Qtrly Rev. Growth | 58.4 % |
| Gross Profit (p.s.) | 0.2 |
| Sales Per Share | 0.48 |
| EBITDA (p.s.) | 0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 60 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | 17.78 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 6.95 |
| Price to Cash Flow | 20.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|